StocksMedium•30 September 2026•
1 min read
US Court Rules Liquidia Infringed United Therapeutics Patents
Key Facts
1The District Court ruled that two of the six claims asserted against Liquidia are valid and infringed regarding the '327 patent.
2The Court directed parties to submit a form of judgment specifying the proposed remedy within one week.
The U.S. District Court ruled that two of the six claims asserted against Liquidia regarding the '327 patent are valid and infringed. GlobeNewswire reported that the Court directed the parties to submit a form of judgment specifying the proposed remedy within one week, marking a development in the ongoing Hatch-Waxman litigation between Liquidia and United Therapeutics.
LQDA closed at $70.69 on September 29, 2026, while UTHR closed at $481.47 on the same date. The litigation centers on U.S. Patent No. '327, with United Therapeutics alleging infringement by Liquidia's respiratory disease treatments, a ruling that could potentially delay product commercialization or necessitate royalty payments.